Patient choice in prostate cancer: two pills, one preference
NCT ID NCT03314324
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This trial asks men with advanced prostate cancer which of two oral medications they prefer: the experimental drug ODM-201 or the approved drug enzalutamide. Both work by blocking male hormones that fuel cancer growth. Participants will take each drug for a period and then answer a questionnaire about their experience, including side effects and convenience. The goal is to see if one treatment is more acceptable to patients, which could help doctors tailor therapy to individual needs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ODM-201 (an experimental androgen receptor inhibitor) and enzalutamide (an approved androgen receptor inhibitor)
- What this could lead to
- If patients clearly prefer one drug over the other, it could guide treatment choices and improve quality of life for men with advanced prostate cancer.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The study focuses on patient preference, not on which drug is more effective, and individual experiences may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE-RESISTANT PROSTATE (CRPC) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France